GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Notes Receivable

Arctic Bioscience AS (OSL:ABS) Notes Receivable : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Notes Receivable?

Arctic Bioscience AS's Notes Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Arctic Bioscience AS Notes Receivable Historical Data

The historical data trend for Arctic Bioscience AS's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS Notes Receivable Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Arctic Bioscience AS Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Arctic Bioscience AS Notes Receivable Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Arctic Bioscience AS Business Description

Traded in Other Exchanges
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. The company is developing a novel, oral drug candidate (HRO350) for the treatment of mild-to-moderate psoriasis. The company operates geographically in Norway, Americas, Europe, and APAC, with majority of the revenue deriving from Europe.

Arctic Bioscience AS Headlines

No Headlines